ETOP 23-22 RAISE: A single-arm phase II study of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502092-33-00

Acronym

ETOP 23-22 RAISE

Enrollment

Registered

2024-02-19

Start date

2024-05-31

Completion date

Unknown

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive-disease small cell lung cancer and high SLFN11-expression

Brief summary

Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1)

Detailed description

• Progression-free survival (PFS) • Overall survival (OS) • Disease control rate (DCR) by investigator assessment (according to RECIST v1.1) • Adverse events according to CTCAE v5.0

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGTecentriq 840 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1)	—

Secondary

Measure	Time frame
• Progression-free survival (PFS) • Overall survival (OS) • Disease control rate (DCR) by investigator assessment (according to RECIST v1.1) • Adverse events according to CTCAE v5.0	—

Countries

France, Germany, Italy, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026